The mission of the National Institute of Neurological Disorders and Stroke (NINDS) is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease. NINDS is a component of the National Institutes of Health (NIH), the leading supporter of biomedical research in the world. NINDS conducts research and clinical studies to find better ways to prevent, treat, and ultimately cure disorders such as hydrocephalus.
The NINDS helps support the Hydrocephalus Clinical Research Network (HCRN), a collaboration of pediatric neurosurgery centers working together to improve the lives of children with hydrocephalus. The HCRN centers pool their hydrocephalus patient populations to more rapidly study the potential for improved treatments. The HCRN conducts multiple, simultaneous studies at its centers and maintains a substantial registry of patients and procedures.
Cellular mechanisms
Hydrocephalus is a relatively common developmental abnormality, but its underlying mechanisms are not well understood. NINDS supports a wide range of studies that explore the complex mechanisms of normal and abnormal brain development.
For example, NINDS-funded researchers are trying to find gene mutations associated with congenital hydrocephalus. NINDS also supports research exploring how hydrocephalus affects brain nerve networks and brain function.
The early stages of brain development play an important but understudied role in the development of hydrocephalus. NINDS-funded researchers are investigating how signals in the amniotic fluid and early CSF instruct neural stem cell behavior during the pivotal early stages of brain development. This research will help scientists better understand and diagnose disorders like congenital hydrocephalus.
Other NINDS-funded researchers are examining the cellular mechanisms involved in hydrocephalus in order to help identify hydrocephalus risk factors. The results will potentially improve diagnosis, genetic risk assessment, and treatment.
Diagnosis and treatment
Normal Pressure Hydrocephalus may account for more than 5 percent of all cases of dementia. Unlike most other causes of dementia, NPH can sometimes be reversed with treatment. However, not all surgeries are successful, and researchers do not know why some people respond to treatment and others do not. NINDS-funded researchers are developing new imaging methods to help physicians determine whether shunt surgery is likely to improve the cognitive and motor difficulties that often accompany NPH.
Shunts are the standard treatment of hydrocephalus, but shunts can malfunction, and repeated surgery may be needed. The rate of malfunction of shunts in children is estimated to be 40 percent in the first year after placement, and 10 percent per year after that. Current methods for diagnosing shunt malfunctions are often invasive and expensive. To help solve this problem, NINDS-funded researchers are working to develop a safe, cost-effective method for diagnosing shunt malfunctions using ultrasound.
Not only do shunts malfunction, they also carry a high risk of infection. NINDS-funded scientists are attempting to identify and describe all the microorganisms present in CSF when shunts are placed, revised, and infected in order to improve prevention and treatment of CSF shunt infection.
More information about hydrocephalus research supported by the NINDS and other NIH Institutes and Centers can be found using NIH RePORTER (projectreporter.nih.gov), a searchable database of current and past research projects supported by NIH and other federal agencies. RePORTER also includes links to publications and resources from these projects.